Thalidomide
- Generic Name
- Thalidomide
- Brand Names
- Thalomid, Thalidomide BMS (previously Thalidomide Celgene), Thalidomide Lipomed
- Drug Type
- Small Molecule
- Chemical Formula
- C13H10N2O4
- CAS Number
- 50-35-1
- Unique Ingredient Identifier
- 4Z8R6ORS6L
- Background
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators li...
- Indication
Thalidomide is primarily used for the acute treatment and maintenance therapy to prevent and suppress the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL).
- Associated Conditions
- Aphthous Stomatitis, Chronic Graft-Versus-Host Disease, Erythema Nodosum Leprosum, Multiple Myeloma (MM), Primary Amyloidosis, Uremic Pruritus, Waldenström's Macroglobulinemia (WM), Moderate Erythema nodosum leprosum, Refractory Graft versus host disease, Severe Erythema nodosum leprosum, Treatment naive multiple myeloma
- Associated Therapies
- -
Irinotecan Plus Thalidomide in Second Line Advanced Gastric Cancer
- First Posted Date
- 2015-03-30
- Last Posted Date
- 2015-03-30
- Lead Sponsor
- Wang Jufeng
- Target Recruit Count
- 900
- Registration Number
- NCT02401971
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
Gefitinib Combined With Thalidomide to Treat NSCLC
- First Posted Date
- 2015-03-12
- Last Posted Date
- 2015-03-12
- Lead Sponsor
- Bai Jun
- Target Recruit Count
- 380
- Registration Number
- NCT02387086
Retreatment and Its Efficiency of Thalidomide for Vascular Malformation Patients With Failure of First Course Treatment
- Conditions
- Interventions
- First Posted Date
- 2014-11-26
- Last Posted Date
- 2016-04-21
- Lead Sponsor
- Zhizheng Ge
- Registration Number
- NCT02301949
- Locations
- 🇨🇳
Department of Gastroenterology, Renji Hospital, Shanghai Institute of Digestive Diseases, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Clarithromycin Plus CTd Regimen for Patients With Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2017-09-06
- Lead Sponsor
- Jinling Hospital, China
- Target Recruit Count
- 130
- Registration Number
- NCT02248428
- Locations
- 🇨🇳
Jinling Hospital, Nanjing, Jiangsu, China
Efficacy of Thalidomide in Preventing Chemotherapy-induced Delayed Nausea and Vomiting
- Conditions
- Interventions
- First Posted Date
- 2014-07-29
- Last Posted Date
- 2016-08-24
- Lead Sponsor
- China Medical University, China
- Target Recruit Count
- 642
- Registration Number
- NCT02203253
- Locations
- 🇨🇳
The First Hospital of Liaoning Medical University, Jinzhou, Liaoning, China
🇨🇳The First Hospital of China Medical University, Shenyang, Liaoning, China
🇨🇳Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2014-05-23
- Last Posted Date
- 2015-06-26
- Lead Sponsor
- Prof Jamie Cavenagh
- Target Recruit Count
- 54
- Registration Number
- NCT02145715
- Locations
- 🇬🇧
Birmingham Heartlands Hospital, Birmingham, UK, United Kingdom
🇬🇧St Bartholomew's Hospital, London, United Kingdom
🇬🇧University College London Hospitals NHS Foundation Trust, London, United Kingdom
PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma
- First Posted Date
- 2014-03-13
- Last Posted Date
- 2021-03-15
- Lead Sponsor
- Huiqiang Huang
- Target Recruit Count
- 264
- Registration Number
- NCT02085655
- Locations
- 🇨🇳
Department of Medical Oncology, Sun Yat-sen University Cancer Center,, Guangzhou, Guangdong, China
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
- First Posted Date
- 2013-12-03
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 240
- Registration Number
- NCT01998971
High-dose Dexamethasone Combining Thalidomide Versus Dexamethasone Mono-therapy for Management of Newly-diagnosed ITP
- First Posted Date
- 2013-11-05
- Last Posted Date
- 2016-04-20
- Lead Sponsor
- Shandong University
- Registration Number
- NCT01976195
- Locations
- 🇨🇳
Qilu hospital, Shandong University, Jinan, Shandong, China
Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT)
- Conditions
- Interventions
- First Posted Date
- 2013-08-23
- Last Posted Date
- 2019-04-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT01927718
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.